Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients That Are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- 06 Nov 2019 Results (n=57; as of 12 Jul 2019) of preliminary analysis assessing safety data of patients with CLL who were either treatment naive or receiving treatment with a BTK inhibitors, released in the 61st Annual Meeting and Exposition of the American Society of Hematology
- 08 Oct 2019 Planned number of patients changed from 108 to 123.
- 07 Dec 2018 Planned initiation date (estimated date of first participant enrolment) changed from 3 Dec 2018 to 13 Dec 2018.